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The optimum treatment of chronic active hepatitis (CAH) is unknown. Various 
immunosuppressive agents have been used in the past1. The use of prednisolone has been 
found to be beneficial in patients with severe chronic active hepatitis2. The criteria for 
treatment remain uncertain3. Long term follow-up of chronic active hepatitis of moderate 
severity treated with prednisolone showed that hepatitis B virus (HBV) associated chronic 
active hepatitis progressed more frequently to cirrhosis than non HBV associated chronic 
active hepatitis treated in the same way4. Another study showed that HBV associated CAH of 
severe degree responded less well 10 prednisolone than non HBV associated CAH but 
patients so treated had a better chance of survival than control patients. A more recent paper 
has implied that treatment of HBV5 associated CAH with prednisolone was positively 
harmful6. 
 Recent evidence suggests that sulphasalazine has an immunosuppressive effect in 
addition to its anti-inflammatory and anti-bacterial effects7. It has been reintroduced for the 
treatment of rheumatoid arthritis with apparent benefit8. For this reason we have used 
sulphasalazine for the treatment of HBV associated chronic active hepatitis, and in this paper 
report the results of a small pilot study. 
Patients and methods 
Five patients were studied. All were intravenous drug abusers who had been referred to us 
from the Drug Advisory and Treatment Centre at the Charitable Infirmary. Each patient was 
physically examined; stigmata of drug abuse, tattoos and stigmata of chronic liver disease 
were sought. Haematological and biochemical parameters were checked including alanine and 
aspartate aminotransferase levels and the presence of hepatitis B surface antigen (HBsAg) was 
sought. Liver biopsy was carried out, following informed consent. 
Histological diagnosis was made in accordance with the criteria suggested in a review by the 
International Group as published in the Lancet9. Each patient was treated with sulphasalazine 
one gram four times daily for one week followed by one gram three limes daily for six 
months. No other form of therapy was given. Each patient was seen at monthly intervals 
during therapy when clinical and biochemical parametres were checked. After six months 
therapy each patient was readmitted to hospital, clinical examination and laboratory tests were 
repeated and a second liver biopsy performed. Patients were asked if they had ceased drug 
abuse and if they had complied with prescribed medication. 
Results 
All patients were male, aged 20-26 (mean 24) years. Duration of drug abuse was nine to 48 
(mean 30) months. All admitted to sharing syringes. All were HBsAg positive. Four patients 
were jaundiced at the time of initial biopsy; the non-jaundiced patient had a history of 
jaundice. In those patients who were jaundiced this cleared during the course of therapy and 
did not recur. No patient developed any other symptom referable to their liver disease. 
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 Serum alanine and aspartate aminotransferase levels are tabulated in Tables 1 and 2. In 
all patients except one (LC) they had returned to normal or near normal levels by the end of 
six months. These histological findings are tabulated in Table 3. One patient (JM) had 
cirrhosis on his initial biopsy, this was confirmed on repeal biopsy. One patient (LC) had 
increased fibrosis on repeat biopsy; the degree of fibrosis was unchanged on a third biopsy 
although there was some reduction in the cellular infiltrate. Three patients showed 
histological improvement. All patients claimed to have ceased abusing drugs, four claimed 
compliance with prescribed medication, one (LC) admitted taking sulphasalazine 
intermittently only. 
Discussion 
Four of five patients with HBsAg positive chronic active hepatitis treated with sulphasalazine 
showed marked 
Table 1 
Serum asparate aminotransferase u/1 (normal = 45<u/l) 
Patient Diagnosis One Month Six Months Twelve Months 
L.C. 200 78 360 112 
J.H. 2090 156 50 – 
J.M. 3540 51 23 – 
J.R. 1168 230 34 – 
S.B. 400 36 15 – 
Table 2 
Serum alanine aminotransferase u/1 (normal = 40<u/l) 
Patient Diagnosis One Month Six Months Twelve Months
L.C. 54 45 126 70 
J.H. 1100 49 42 – 
J.M. 1669 33 30 – 
J.R. 680 – 34 – 
S.B. 174 36 20 – 
Table 3 
Summary of histological findings 
Patient Biopsy Cellular Activity Fibrosis Cirrhosis 
L.C. 1st 
2nd 
3rd 
+ + 
+ + 
+ 
+ + 
+ + + 
+ + + 
– 
– 
J.H. 1st 
2nd
+ + + 
+
+ + 
+
– 
–
J.M. 1st 
2nd
+ + + 
+ +
+ + + 
+ + +
Present 
Present
J.R. 1st 
2nd
+ + 
+
+ + 
+
– 
–
S.B. 1st 
2nd 
+ + 
+ 
+ + + 
+ + 
– 
– 
clinical and biochemical improvement. We were impressed by the alertness and general well-
being of patients treated in this way compared with those treated with prednisolone and 
azathiaprine which was our previous practice. These four patients showed histological 
improvement (one had cirrhosis on his initial and repeat biopsy). The fifth patient (LC) felt 
better, but his biochemical parameters after initial improvement, disimproved. Repeat biopsy 
of this patient showed increased fibrosis but no alteration in cellular activity. This last patient 
was switched from sulphasalazine to prednisolone five milligrams twice daily and 
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azathioprine 50 milligrams daily for a further six months at the end of which his enzymes 
were less elevated and liver biopsy showed less cellular activity. Only then did he admit he 
had taken sulphasalazine only occasionally after the first three weeks of therapy; initial 
biochemical response suggests that he may have improved had he persisted with therapy. 
 The treatment of chronic active hepatitis remains unclear. In the past various 
immunosuppressive agents have been used including 6-mercaptopurine, azathioprine, 
chlorambucil and cyclophosphamide. Several HBsAg negative CAH has been shown to 
respond to therapy with prednisolone2. The combination of ten mgs. of prednisolone with 50 
mgs. of azathioprine appears to be the safest, most effective, regimen10. There is no known 
therapy at present for HB,Ag positive CAH. 
 Sulphasalazine appears to have several different actions. It has an antibacterial effect 
on the gut11. It has an anti-inflammatory effect12. It inhibits numerous enzymes13,14. 
Sulphasalazine inhibits prostaglandin synthesase in vitro15 and in human colon specimens16. 
However, another report suggests that the major effect is on prostaglandin dehydrogenase, 
inhibiting this enzyme and thus allowing a higher concentration of prostaglandin to form17. 
 Recently sulphasalazine has been shown to have immunosuppressive effects. Laursen18 
presented data which showed that a prior inoculation of live ascitic tumour cells into the 
caecal lumen of mice protected against a subsequent graft with the tumour cells and that this 
protection was abolished by pre treatment with sulphasalazine. Implantation tumours were 
seen only in animals treated. Furthermore, the response to initial immunisation was also 
changed in mice treated with sulphasalazine, the protective immune response seen in non-
treated animals was suppressed. Rubinstein and his colleagues7 showed that in the active stage 
of ulcerative colitis and idiopathetic proctitis circulating complement receptor positive cells 
were increased whereas T cell percentage and lymphocyte functions were decreased. In severe 
forms of ulcerative EAC phagocytosing esterase positive cells, indicative of activated 
monocytes, were demonstrated. Treatment with sulphasalazine reversed these immunological 
changes. 
 Sulphasalazine has recently been re-introduced for treatment of rheumatoid arthritis8 
with apparent clinical benefit together with a fall in C-reactive protein and erythrocyte 
sedimentation rate. It was felt that this action was not due to the salicylate effect of 
sulphasalazine but could have been due to either its anti-bacterial or immunosuppressive 
effects. 
 The place of sulphasalazine in the management of chronic active hepatitis is not yet 
clear. Our results suggest that it may provide a safe and effective drug for the treatment of 
HBsAg positive chronic active hepatitis. In non HBV associated disease it is possible that 
sulphasalazine also has a place in the management of less severe chronic active hepatitis, or in 
severe cases it may be possible to use it to maintain an improvement obtained with steroids in 
the same way as it is generally used in ulcerative colitis19,20. We believe the results from this 
pilot study warrant controlled trials to determine the exact role of sulphasalazine in the 
treatment of chronic active hepatitis. 
Summary 
In a pilot study we assessed the efficacy of sulphasalazine in the treatment of hepatitis B virus 
(HBV) associated chronic active hepatitis (CAH). All five patients showed a clinical and 
biochemical response at one month. Four patients showed clinical, biochemical and 
pathological improvement at six months. The fifth patient had deteriorated biochemically 
between the first and sixth month and histology showed increased fibrosis with no change in 
the degree of cellular activity. This patient subsequently admitted that he had only taken 
sulphasalazine for the first three weeks. 
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This study suggests that controlled trials are needed to test the efficacy of Sulphasalazine in 
the treatment of HBV associated chronic active hepatitis and probably also in mild cases of 
non-HBV associated chronic active hepatitis. Its role in maintaining remission induced by 
corticosteroids and azathioprine in severe chronic active hepatitis should also be determined. 
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may not match that of the original. 
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